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ABSTRACT
Status epilepticus (SE) is a common diagnosis in critically ill patients that may bear significant 
morbidity and mortality. Nowadays it is defined as continuous seizure activity lasting for more than 5 mins 
and requiring a specific treatment. A generalised convulsive state is a medical emergency burdened 
by high mortality, especially in the elderly, because repeated seizures swiftly induce significant 
metabolic and cardiocirculatory derangement. Two different kinds of SE are commonly recognised, 
depending on the presence of convulsion: convulsive SE and non-convulsive SE, which have different 
electroencephalographic patterns and require different therapies. In this review we provide an overview 
of this intriguing issue, focussing on critically ill patients. 
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INTRODUCTION
Status epilepticus (SE) is a common diagnosis 
in critically ill patients that may bear significant 
morbidity and mortality. For this reason it is 
extremely important that it is properly diagnosed 
and treated. According to the traditional criteria, 
SE is defined as continuous seizure activity lasting 
30 mins or as two or more discrete seizures 
between which consciousness is not fully regained.1 
Numerous studies have recently revised this 
definition assuming that seizures lasting more than 
5 mins require the same treatment as that used for 
traditional SE.2,3 This is because the mechanisms 
responsible for the seizure’s self-termination 
fail, thus impairing homeostasis of the body and 
thereby causing the condition to become life-
threatening due to the deterioration of various 
organs and systems as well as from direct damage 
to the brain cells related to neurotransmitter 
release.3 Neuronal injury results from several 
cellular alterations involving extracellular and 
intracellular ionic balances, as well as the 
activation of inflammatory processes and the cell 
death mechanism. 
The opening of the blood—brain barrier during 
SE has a short-term pro-epileptic effect, 
causing equilibration of serum electrolytes with 
cerebrospinal fluid. This results in an increased 
interstitial space, a lowered extracellular Ca2+ 
concentration, and the facilitation of neuronal 
excitability.4 The release of cytokines and 
neuropeptides with a variety of cytological and 
chemical reactions affects the brain vascular 
permeability and determines pro-inflammatory and 
immune reactions.5 The most well-known cytokines 
include interleukin (IL)-6, IL-1β, tumour necrosis 
factor α, and the activation of the IL-1 Type 1 
receptor/Toll-like receptor signal pathway. Seizures 
trigger neuronal death by an active form of necrosis 
requiring a mitochondrial death programme and/or 
the activation of a caspase cascade.6
Convulsive Status Epilepticus 
Convulsive status epilepticus (CSE) is a condition 
characterised by epileptic seizures associated 
with rhythmic contractions of the extremities, 
tonic–clonic movement of the limbs, altered mental 
state (coma, lethargy, confusion), and possible 
focal neurological deficits in the postictal period.
Non-Convulsive Status Epilepticus 
Non-convulsive status epilepticus (NCSE) is 
defined as altered consciousness or behaviour 
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for 30 mins or more, the absence of overt clinical 
signs of convulsive activity during that period, and 
the electroencephalographic (EEG) confirmation 
of seizures or activity that responds to treatment 
along with improved consciousness.7 NCSE is 
increasingly recognised as a common occurrence 
in the intensive care unit (ICU) but in coma 
patients continuous lateralised epileptiform 
discharges (coma–LED) need to be distinguished 
from generalised epileptiform discharges (coma-
GED), and it is often difficult to understand if the 
coma is caused by SE or by an underlying brain 
disorder and thus correlate this with suitable 
prognosis and therapy.8
Refractory Status Epilepticus
SE is defined as refractory when it does not 
respond to standard therapeutic regimens. Brophy 
et al.2 suggest considering patients to be in 
refractory status epilepticus (RSE) whenever they 
continue manifesting clinical or EEG signs after an 
adequate dose of benzodiazepine (BZD) followed 
by a second anti-epileptic drug (AED) which is 
deemed effective. The number of AEDs to which 
patients have not responded that is required 
for a diagnosis of RSE, and whether or not to 
consider the duration of the SE from the initiation 
of treatment for the purpose of classification, 
remain controversial.
EPIDEMIOLOGY
SE, and in particular NCSE, has been identified in 
many studies as a very common nosological entity 
in ICUs, with a higher incidence in neurological 
ICUs partly due to medical and metabolic 
conditions, and partly due to the drugs used 
that predispose patients to the condition.9 
The incidence of SE in Europe varies from 
9.9/100,000 in Switzerland and 10.7/100,000 in 
Italy10 to 17.1/100,000 in Germany,11 with a bimodal 
distribution involving a high incidence in infants 
<1 year of age and in the elderly (>60 years of 
age). In the event of subarachnoid haemorrhage, 
epileptic seizures are known to be a very common 
sequela, and some recent scientific evidence 
shows an underestimated frequency of the non-
convulsive type in these patients, especially in 
those subject to sedation.12 Even intraparenchymal 
haemorrhage has proven to be complicated by 
SE in a high percentage of cases (i.e. 18-21%), due 
to SE being a factor in midline shift, increased 
haemorrhaging, and a worsening of the outcome. 
Ischaemic and haemorrhagic stroke have been 
shown to be correlated with CSE and NCSE in 
such a significant percentage of cases as to 
suggest the early use of EEG monitoring to reveal 
the presence of periodic lateralised epileptiform 
discharges, which were followed in a study by 
Mecarelli et al.,13 by SE in 70% of cases. To study 
the incidence of NCSE within the spectrum of 
SE, some authors have proposed associating 
prolonged video-EEG recording with standard 
EEG, reaching a diagnosis of NCSE in 59% of cases 
studied on the basis of a specific clinical suspicion 
and in 41% of cases in patients with no clinical 
evidence. This finding yet again shows the utility 
of EEG monitoring.14
DIAGNOSIS AND 
ELECTROENCEPHALOGRAPHIC
PATTERNS
The initial diagnosis of SE is still based on the 
clinical assessment of altered motor performance 
and mental status, but it must inevitably rely on 
prolonged EEG monitoring in some cases where 
findings from the first two assessments are not 
temporally correlated with the EEG findings, both 
during or after the SE, or in particular forms of SE, 
such as NCSE. Table 1 shows the characteristic 
findings for each of the three assessments 
associated with the different forms of SE. 
Remarkably, EEG criteria for convulsive SE have 
been clearly delineated, but a combination of 
clinical and EEG criteria have to be met for 
NCSE diagnosis.
Clinical manifestations of SE in the variant of 
NCSE in patients admitted to intensive care can 
be blurred due to the underlying condition and 
drugs administered, such as anaesthetics, muscle 
relaxants, and anticonvulsants. Furthermore, 
there are no pathognomonic encephalographic 
characteristics that precisely identify SE to 
differentiate it from electrical epiphenomena 
caused by cerebral dysfunction. In fact, although 
the significant generalised activity of spike 
discharges is indicative of severe encephalopathy, 
this can more often be associated with anoxic 
phenomena or to NCSE.8 Furthermore, advanced 
stages of coma are frequently accompanied by 
continuous or periodic epileptiform phenomena, 
considered by some to be the very cause of the 
severe encephalopathy and the coma. Holtkamp 
and Meierkord et al.15 suggested formulating a 
diagnosis of NCSE only if, in addition to EEG 
abnormalities, there is clinical evidence of epilepsy 
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derived from the patient’s clinical history or if 
episodes of epileptic seizures or SE have occurred. 
In 2010, two further definitions were introduced 
to attempt to better clarify this complex clinical 
situation — coma-GED and coma-LED — definable 
on the basis of the EEG and that can effectively 
distinguish NCSE from comatose NCSE, as 
described previously.8 
Lastly, subtle SE is a form of NCSE that arises 
from insufficiently treated SE. It may be an 
unrecognised cause of coma.16 The distinctive 
features include a comatose state and the absence 
of prominent motor features. Nevertheless, there 
can also be discrete muscle twitching, and 
EEG tracings mostly show generalised periodic 
discharges, although lateralised and regional 
discharges can also occur. The most recent 
guidelines put forth by the Neurocritical Care 
Society2 and by the European Society of Intensive 
Care Medicine17 recommend continuous EEG 
monitoring for comatose patients, patients with 
intracranial haemorrhage, and patients with 
recent clinically overt epileptic seizures without 
normalisation. In particular, continuous EEG 
monitoring is recommended for at least 48 h for 
coma patients to assess the presence of NCSE.
NON-EPILEPTIC CONDITIONS THAT 
MIMIC THE MANIFESTATIONS OF NCSE 
A number of conditions can mimic NCSE 
without there being periodic or rhythmic EEG 
abnormalities. These include migraine aura, 
transient global amnesia, transient ischaemic attack, 
stupor, and dissociative disorders. Pseudostatus 
epilepticus can present in various forms, such as 
with bizarre motor features or a simulation of loss or 
impairment of consciousness without motor 
features. None of these conditions is accompanied 
by EEG alterations. In the impossibility of EEG 
monitoring, 2 mg of intravenous (IV) lorazepam 
(LZP) can be administered to clarify the diagnosis 
of NCSE.15
There are, however, situations treated in the ICU 
that can give rise to confusion, both clinically 
and electroencephalographically with NCSE. 
Table 1: Clinical features and electroencephalography (EEG) pattern of convulsive and non-convulsive 
status epilepticus.
CLINICAL FEATURES EEG PATTERN
CONVULSIVE
GENERALISED
Tonic–clonic 
seizures
Tonic phase: Sustained powerful 
muscle contraction, which 
arrests ventilation
Chronic phase: Alternating 
contraction and relaxation 
(rhythmic jerk), causing a 
reciprocating movement which 
could be bilaterally symmetrical 
or ‘running’ movements; possible 
urinary or faecal incontinence,  
possible morsus
Tonic phase: Progressively 
higher amplitude and lower 
frequency discharge pattern 
observed simultaneously in 
both cortical hemispheres, 
reaching a maximum of 10 Hz
Chronic phase: Slow spikes 
develop progressively into 
repetitive complexes of high-
amplitude spike-and-slow-
wave activity
Myoclonic 
status
Normal or moderately impaired 
consciousness and generalised 
myoclonia (predominantly 
affects the upper extremities 
and shows some asymmetry)
Anoxic coma
Slowing of background rhythm 
and high-voltage generalised  
spike and wave discharges
Normal background activity 
with high amplitude, 5 to 15-Hz 
rapid bursts of generalised 
polyspikes synchronous with 
the myoclonia
FOCAL
Epilepsia 
partialis 
continua
Consciousness usually preserved 
Focal motor clonic seizures 
without Jacksonian march; 
lasting for at least 60 mins and 
often for hours, days, weeks,  
or even longer; often  
treatment resistant
Few or no paroxysmal 
abnormality 
Irregular 0.5-3 Hz slowing in 
the frontocentral region with 
reduction of beta-activity
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Post-anoxic encephalopathy often leads to EEG 
alterations characterised by sharp generalised 
periodic, single, or grouped discharges, which 
appear within a flat or slow-activity background; 
myoclonus can arise from the first day, and 
is usually sensitive to stimuli. The point of 
administering an AED in these cases seems purely 
‘cosmetic’ and has no evident benefit for the 
patient;15 even so, diminishing myoclonus can 
simplify treatment for nurses and family. A recent 
article suggests that in some rare cases, low 
frequency and non-progressive epileptiform 
discharges can correspond to NCSE rather than 
to post-anoxic encephalopathy. In these events, 
propofol can ‘unmask’ the underlying state of 
epilepsy, revealing the absence of biological 
activity and, therefore, can be used as a ‘diagnostic’ 
drug second to BZD.18
Table 1 continued.
CLINICAL FEATURES EEG PATTERN
NON- 
CONVULSIVE
GENERALISED
Typical absence 
status
Impaired consciousness; 
behavioural changes: 
disorientation, decreased 
spontaneity, slow speech, 
hallucinations; rhythmic blinking; 
slight myoclonic jerking;  
abrupt onset
2-3 Hz spike-wave discharges
Interictal background activity 
normal
Late-onset 
absence status
Impaired consciousness; 
behavioural changes: 
disorientation, decreased 
spontaneity, slow speech, 
hallucinations; rhythmic blinking; 
slight myoclonic jerking
Rarely 2-3 spike-wave 
discharges
More frequently 0.5-4 Hz 
spike-wave discharges
FOCAL
Complex 
partial status 
epilepticus 
Impaired consciousness; 
‘epileptic twilight state’ 
with confusion and strange 
behaviour; oral or manual 
automatism; gradual 
development of symptoms
Variable with focal and 
bilateral spike and spike-
waves; surface EEG with good 
sensitivity
Subtle status 
epilepticus
Loss of consciousness; no 
or subtle movements such 
as rhythmic twitching of the 
arms, legs, trunk or facial 
muscles, tonic eye deviation, or 
nystagmoid eye jerking
Generalised or lateralised spike 
or spike-wave discharges
Flat periods
COMATOSE
Coma with 
generalised 
epileptiform 
discharges  
(coma-GED)
Anoxic coma: possible 
myoclonias and other motor 
abnormalities disappearing with 
anaesthesia
Impaired consciousness after 
intoxication, vascular infarcts, 
cardiopulmonary arrest, 
infections, space-occupying 
lesions, and metabolic disorders 
may present as various degrees 
of coma
Continuous or periodic 
generalised spikes and waves 
with flat periods in between
Burst suppression pattern
Bilateral triphasic waves with 
and without spikes
EEG pattern tends to mirror 
the depth of coma
Coma with 
lateralised 
epileptiform 
discharges 
(coma-LED)
Focal or lateralising neurologic 
signs resulting from focal 
brain lesions (in most cases 
acutely acquired) or diffuse 
abnormalities (rarely)
Continuous focal spiking 
PLEDs (periodic lateralised 
epileptiform discharges)
Bi-PLEDs (bilateral PLEDs)
Unilateral burst suppression
Unilateral triphasic waves
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SE may occur in the setting of several internal 
or neurological diseases. In some forms of 
encephalopathy, of varying aetiology (i.e. 
metabolic, toxic, or immunologic), the clinical 
and EEG findings can be similar to those of NCSE, 
but treatment with BZD does not impact upon 
the patient’s condition, which actually improves 
with treatment of the base disease. Some 
authors highlight, for example, the importance of 
considering anti-neutrophil cytoplasmic antibody 
(ANCA) dosage in patients with SE of unclear 
origin, and propose to promptly start adequate 
immunotherapy in patients with inflammatory 
changes at brain magnetic resonance imaging 
(MRI), with or without other systemic signs of 
ANCA-associated vasculitis.19 Monoclonal antibody-
based B cell depletion may represent a therapeutic 
alternative for antibody-mediated encephalopathy 
achieving a good outcome. Other authors have 
reported, therefore, a case of NCSE induced by 
acute hypothyroidism in a critically ill patient, and 
recommended studying the thyroid function in 
those patients presenting with unexplained SE 
accompanied with acute anasarca.20
NEURONAL AND CLINICAL 
CONSEQUENCES
A generalised convulsive state is a medical 
emergency burdened by high mortality, especially 
in the elderly, because repeated seizures swiftly 
induce metabolic and cardiocirculatory failure, 
hyperthermia, cerebral oedema, and potentially 
irreversible neuron damage. Excessive and 
prolonged muscular twitching leads to increased 
creatine kinase and, in the most severe cases, 
rhabdomyolysis, hyperkalaemia, hypocalcaemia, 
myoglobinuria, and potential renal failure; 
metabolic acidosis, caused by depletion of 
glycogen stores and anaerobic glycolysis, is also 
frequent. Many patients can develop respiratory 
acidosis by pulmonary aspiration, diminished 
respiratory drive, and efficacy of the skeletal- 
muscle pump. Lastly, a massive amount 
of circulating catecholamines can cause 
cardiac arrhythmias, cardiomyopathy (especially 
Takotsubo), and hyperglycaemia.
Many animal studies have shown how prolonged 
epileptic seizures, even non-convulsive, can lead 
to neuron damage. The increase in extracellular 
glutamate at excitotoxic levels,21 associated with 
EEG: electroencephalographic; HR: heart rate; BP: blood pressure; AED: anti-epileptic drug; 
IV: intravenous; IM: intramuscular; PO: oral administration; PR: rectal administration; SE: status epilepticus; 
MRI: magnetic resonance imaging; CT: computed tomography; LP: lumbar puncture; RSE: refractory 
status epilepticus.
Table 2: Management of status epilepticus.
Immediate 
measures 
(0-5 mins)
Non-invasive or invasive airway protection and oxygenation
Vital signs monitoring (O2 saturation, HR, BP)
Fingerstick blood glucose
Establish intravenous access
Laboratory tests: complete blood count, electrolytes, liver enzymes, arterial blood gases, 
toxicology screen, serial troponins, AED blood levels
Emergent initial AED therapy (if no IV access available, give midazolam IM, PO, or intranasally, or 
diazepam PR)
Fluid resuscitation
If serum glucose <60 mg/dl, administer 100 mg thiamine first and then 50% dextrose 
Call for EEG
Immediate 
measures 
(5-15 mins)
Neurological examination
Urgent AED therapy for SE control
Vasopressor support if needed
Continuous EEG monitoring
Urgent measures
(15-60 mins)
Urinary catheter
Depending on clinical presentation: intracranial pressure monitoring and neurological diagnostic 
testing (MRI, CT, LP)
RSE measures
(20-60 mins 
after 2nd AED)
RSE therapy if needed
EEG continually running for titrating therapy and monitoring AED response
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an increased lactate/pyruvate ratio, can bring on 
cellular swelling, increased intracranial pressure, 
and cellular death, in addition to producing 
free radicals, inflammation, gliosis, atrophy, and 
synaptic reorganisation. A recent study also 
demonstrated that brief seizures result in structural 
and functional brain alterations, but confirmed 
that those caused by prolonged seizures are 
considerably more severe.22 A number of anecdotal 
studies using MRI found cerebral acute oedema 
and chronic atrophy, as well as evidence of 
neuronal loss on magnetic resonance spectroscopy 
following NCSE.
Basic research and animal studies are essential 
to understanding the cellular and molecular 
mechanism of SE-induced brain pathology and to 
develop target-specific AEDs for these patients. 
Duration and frequency of epileptic activity 
correlates with the extent of neuron damage, so 
that optimal targeted therapy should provide 
fast and effective control of the SE and treatment 
of the accompanying symptoms during the first 
6-20 mins. 
The duration of SE prior to the initiation of 
treatment influences its effect, regardless of the 
type of drug used. The randomised clinical trial 
on prehospital treatment of SE revealed that the 
placebo group suffered from unfavourable 
consequences of prolonged seizure such as 
acquired neurological deficits or death, confirming 
that the emergency team have a high chance 
of administering BZD during the early SE time 
when the probability of seizure termination with 
drugs is the highest and neuronal damage is not 
yet established.23
According to many authors,24 we suggest a time-
dependent scale: 
• 5-20/30 mins: Early SE (0-5 min interval 
within which most seizures spontaneously 
stop; 5-15 min optimum interval for initiation of 
emergent treatment)
• 20/30-60 mins: Established SE 
(urgent treatment)
• >60 mins: Refractory SE (refractory treatment)
It is important to underscore that an accumulation 
of complications is usually encountered in coma 
patients with SE and it is truly difficult to individuate 
complications due to persistent seizure activity 
from those originating from the causative medical 
disorder or from pharmacological treatments. The 
cause of SE remains the most important prognostic 
factor, with alcohol and AED withdrawal having 
the best outcomes; structural brain injuries such 
as anoxia-ischaemia, vascular lesions, and brain 
tumours have the worst prognosis. A prognostic 
score, the SE severity score (STESS), has been 
developed to predict survival before initiation of 
SE treatment (range: 0-6).25 This score relies on 
the assessment of age, previous history of seizures, 
seizure type (simple partial, complex partial, 
absence of, or myoclonic seizure, generalised 
tonic–clonic seizure, or NCSE in a coma), and the 
extent of consciousness impairment. 
TREATMENT
The main goal is to stop epileptic activity from 
both a clinical and an EEG standpoint. The initial 
treatment strategy involves the management of 
airways, ventilation and haemodynamics, initial 
pharmacological treatment of the seizure, analyses 
to investigate the trigger of the SE, and treatment 
of the identified cause (Table 2). The guidelines 
published in 2012 by the Neurocritical Care Society 
divide the therapeutic strategy into three phases: 
emergent initial AED therapy, urgent control 
AED therapy (in association with anti-epileptic 
maintenance therapy, even if the SE is immediately 
controlled), and potentially refractory therapy 
(reserved for SE failing to respond to the first two 
AEDs administered). The most recent guidelines 
from the USA and Europe on initial therapy 
(Emergent Initial Therapy) advocate the use of 
BZD, preferably IV, although intramuscular and 
rectal administration is possible. LZP is preferred 
for IV therapy, whereas midazolam is indicated for 
intramuscular administration (although it can also 
be administered intravenously, nasally, or orally) and 
diazepam for rectal administration (also available 
in IV form). Clonazepam is not frequently used. 
Controlled studies defining the exact dosages of 
SE treatment are not available. Although all 
reported dosages are derived from observational 
studies, they are widely used, as the dosage 
is based on numerous well-controlled clinical 
studies (Table 3).
The second step is to initiate control therapy of the 
SE (urgent control therapy), unless the trigger is 
resolved and if the seizure appears to have ended. 
For patients whose SE has been resolved, the aim 
is to reach therapeutic levels of an AED and to 
continue the maintenance therapy; for ongoing 
SE, the aim is to stop the seizures. The agents 
generally used are phenytoin/IV fosphenytoin, 
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Table 3: Status epilepticus (SE) and refractory status epilepticus (RSE) pharmacological treatment.
valproic acid, phenobarbital, levetiracetam, or 
continuous infusion of midazolam; IV fosphenytoin 
is generally the drug of choice, except in patients 
with pre-existing epilepsy in whom use of sodium 
valproate is favoured. Serum levels of phenytoin 
and fosphenytoin should be carefully monitored 
due to their nonlinear and saturable kinetics, 
resulting in highly variable concentrations.
DRUG MECHANISMS OF ACTION
INITIAL DOSE & 
ALTERNATIVE 
DOSING
DOSAGES RSE INITIAL DOSE
RSE CI TITRATED 
WITH EEG
DIAZEPAM
Emergency treatment
Enhancement 
of GABA-ergic 
transmission 
(bond with 
GABAA receptor 
and increase of 
CI- conductance 
due to increase of 
channel opening 
frequency)
0.15 mg/kg IV 
up to 10 mg may 
repeat
in 5’ (NCS-EFNS)
0.1 mg/kg IV, 
may repeat in 10’ 
(LICE)
Up to 5 mg/min
FOSPHENYTOIN
Emergency treatment
Urgent treatment
Refractory treatment
Extension of 
voltage-dependent 
Na+ channel 
refractory period
20 mg PE/kg 
IV, may give 
additional 5 mg/
kg (NCS)
Up to 150 mg 
PE/min; may give 
an additional 
dose 10 mins 
after loading 
infusion (NCS)
ISOFLURANE
Refractory treatment
Inhibition of 
NMDA receptor 
Enhancement 
of GABA-ergic 
transmission 
(bond with GABAA 
receptor and 
increase of CI- 
conductance)
0.8-2 vol % (LICE) Titrate with EEG
LIDOCAINE
Refractory treatment
Inhibition of 
voltage-dependent 
Na+ channel
1.5-2 mg/kg 
bolus, may repeat 
only once (LICE 
- alternative 
treatment)
Up to 50 mg/min
LORAZEPAM
Emergency treatment
Enhancement 
of GABA-ergic 
transission (bond 
with GABAA 
receptor and 
increase of CI- 
conductance due 
to increase of 
channel opening 
frequency)
0.1 mg/kg IV up 
to 4 mg may 
repeat in 5-10’ 
(NCS-EFNS) 
0.05-0.1 mg/kg IV, 
may repeat in 10’ 
(LICE)
Up to 2 mg/min 
(IVP)
MIDAZOLAM
Emergency treatment
Urgent treatment
Refractory treatment
Enhancement 
of GABA-ergic 
transmission 
(bond with 
GABAA receptor 
and increase of 
CI- conductance 
due to increase of 
channel opening 
frequency)
0.2 mg/kg IM up 
to 10 mg (NCS)
5-10 mg IM or 5-10 
mg rectal may 
repeat only once;
0.1-0.3 mg/kg IV 
bolus, up to  
4 mg/min;
10 mg PO (the 
only formulation 
officially 
recommended in 
Italy for epilepsy 
treatment) (LICE)
RSE: 0.2 mg/kg 
at 2 mg/min 
(NCS)
RSE/subtle SE: 
0.2 mg/kg bolus 
(EFNS)
RSE: 0.05-2 mg/
kg/h CI
Breakthrough SE: 
0.2 mg/kg bolus, 
increase CI rate 
by 0.05-0.1 mg/
kg/h every 3-4 h 
(NCS) 
RSE/subtle SE: 
0.05-0.4 mg/
kg/h CI (EFNS)
RSE: 0.05-0.4 
mg/kg/h (LICE)
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Table 3 continued.
DRUG MECHANISMS OF ACTION
INITIAL DOSE & 
ALTERNATIVE 
DOSING
DOSAGES RSE INITIAL DOSE
RSE CI TITRATED 
WITH EEG
PENTOBARBITAL
Refractory treatment
Enhancement 
of GABA-ergic 
transmission 
(bond with 
GABAA receptor 
and increase of 
CI- conductance 
due to increase of 
channel opening 
time)
RSE: 5-15 mg/
kg IV, may give 
additional 5-10 
mg/kg; infusion 
rate ≤50 mg/min 
(NCS)
RSE: 0.5-5 mg/
kg/h CI
Breakthrough SE: 
5 mg/kg bolus, 
increase CI rate 
by 0.5-1 mg/kg/h 
every 12 h (NCS)
PHENOBARBITAL
Emergency treatment
Urgent treatment
Refractory treatment
Enhancement 
of GABA-ergic 
transmission 
(bond with 
GABAA receptor 
and increase of 
CI- conductance 
due to increase of 
channel opening 
time)
20 mg/kg IV, may 
give an additonal 
5-10 mg/kg (NCS) 
10-20 mg/kg 
(LICE - alternative 
treatment)
50-100 mg/
min IV, may give 
additonal dose 
10 mins after 
loading infusion 
(NCS)
50-75 mg/
min IV (LICE 
- alternative 
treatment)
RCPSE: 20 mg/
kg IV (EFNS)
RCPSE: 50 mg/
min IV (EFNS)
PHENYTOIN
Emergency treatment
Urgent treatment
Refractory treatment
Extension of 
voltage-dependent 
Na+ channel 
refractory period
20 mg/kg IV, may 
give an additonal 
5-10 mg/kg (NCS) 
18 mg/kg IV 
(EFNS)
In patients already 
treated with 
benzodiazepines 
15-18 mg/kg IV, 
may give an 
additonal 5 mg/
kg (LICE)
Up to 50 mg/
min IV; may give 
additonal dose 
10 mins after 
loading infusion 
(NCS)
PROPOFOL
Refractory treatment
Enhancement 
of GABA-ergic 
transmission 
(bond with 
GABAA receptor 
and increase of 
CI- conductance 
due to increase of 
channel opening 
time)
Block of voltage-
dependent Na+ 
channel
RSE: start at 
20 µg/kg/min, 
with 1-2 mg/
kg loading dose 
(NCS)
RSE/subtle SE: 
start with 2-3 
mg/kg bolus, 
then 1-2 mg/
kg boluses until 
seizure control 
(EFNS)
RSE: 2-5 mg/kg 
bolus (LICE)
RSE: 30-200 µg/
kg/min
Breakthrough SE: 
Increase CI rate 
by 5-10 µg/kg/
min every 5 mins 
or 1 mg/kg bolus 
plus CI titration 
(NCS)
RSE/subtle SE: 
4-10 mg/kg/h CI 
(EFNS)
RSE: 5 mg/kg/h 
CI for at least an 
hour (LICE)
THIOPENTAL
Refractory treatment
Enhancement 
of GABA-ergic 
transmission 
(bond with GABAA 
receptor and 
increase of CI- 
conductance)
RSE: 2-7 mg/kg,  
≤50 mg/min 
(NCS)
RSE/subtle SE: 
3-5 mg/kg bolus, 
1-2 mg/kg every 
2-3 mins until 
control (EFNS)
RSE: 5-7 mg/
kg/20’ then 
50 mg every 
2-3 mins for 
“suppression 
burst” (LICE)
0.5-5 mg/kg/h CI
Breakthrough SE: 
1-2 mg/kg bolus, 
increase CI rate 
by 0.5-1 mg/kg/h 
every 12 h (NCS) 
3.7 mg/kg/h CI 
(EFNS)
3-5 mg/kg/h CI 
(LICE)
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Emergency treatment: initial therapy; urgent treatment: SE control therapy (if SE has been controlled with the 
emergency treatment, the aim is to achieve therapeutic levels of anticonvulsants and establish a maintenance 
therapy — if SE has not been controlled, the aim is to stop the crisis); refractory treatment: drug treatment 
indicated for SE unresponsive within 60 mins of emergency and urgent treatment.
GABAA receptor: γ-aminobutyric acid receptor; NCS: Neurocritical Care Society; EFNS: European 
Federation of Neurological Societies; LICE: Lega Italiana contro l’Epilessia (Italian League Against Epilepsy); 
PE: phenytoin equivalent; IV: intravenous; IM: intramuscular; PO: oral administration; CI: continuous infusion; 
subtle SE: subtle status epilepticus; NMDA receptor: N-methyl-D-aspartate receptor; RSE: refractory 
status epilepticus; RCPSE: refractory continuous partial status epilepticus; AMPA: α-amino-3-hydroxy-5- 
methyl-4-isoxazolepropionic acid; NG: nasogastric administration; PIP3: phosphatidylinositol 3,4,5- 
trisphosphate; Cl: chloride; Ca2+channel: calcium channel; IVP: intravenous pyelogram.
Refractory Status Epilepticus
Control of the SE should be achieved within 
60 mins using the two treatments mentioned 
above. If unsuccessful the SE is considered RSE. In 
this case, it is possible to repeat a bolus of the drug 
used in the second step, or to start an additional 
agent,2 since no data suggest that watchful waiting 
is safer than initiating more aggressive therapy 
immediately. If the intermittent bolus therapy fails, 
it is advisable to use continuous infusion; however, 
it is recommended to first consider boluses of a 
drug not previously used (fosphenytoin/phenytoin, 
levetiracetam, sodium valproate). Bolus doses of 
the agent used for the continuous infusion should 
also be started and repeated, in addition to the 
infusion. If the drug chosen is ineffective it is 
advisable to use another one from the list (Table 3). 
The intensity of the treatment is dictated by the 
EEG findings, with the aim of obtaining burst 
suppression. Conversely, definite indications 
are lacking on what duration of treatment is 
needed to maintain. As a rule, after 24-48 h the 
continuous infusion drug dose is gradually weaned; 
if at this point the patient again shows signs of 
relapse, the prior or a higher dosage is reinstated 
for a greater period of time, with or without an 
additional agent. No data are available indicating 
how much time should pass before a treatment 
DRUG MECHANISMS OF ACTION
INITIAL DOSE & 
ALTERNATIVE 
DOSING
DOSAGES RSE INITIAL DOSE
RSE CI TITRATED 
WITH EEG
TOPIRAMATE
Refractory treatment
Enhancement 
of GABA-ergic 
transmission
Inhibition of 
excitatory 
transmission 
(action on kainate 
and AMPA 
receptor)
Inhibition 
of carbonic 
anhydrase
200-400 mg NG/
PO (NCS)
300-1,600 
mg/day orally 
(divided 2-4 
times daily) 
(NCS)
SODIUM VALPROATE
Emergency treatment
Urgent treatment
Refractory treatment
Increase of PIP3 
levels in the brain
Inhibition of 
voltage-dependent 
Na+ channel
Inhibition of 
voltage-dependent 
Ca2+ channel
Alteration of 
GABA turnover 
resulting in 
inhibition of GABA 
catabolism
20-40 mg/kg 
IV, may give an 
additional 20 
mg/kg (NCS) 
15-30 mg/kg IV 
(LICE - alternative 
treatment)
3-6 mg/kg/
min, may give 
additional dose 
10 mins after 
loading infusion 
(NCS)
1-2 mg/kg/h 
CI (LICE - 
alternative 
treatment)
RCPSE: 25-45 
mg/kg IV 
(EFNS)
RCPSE: Up to 6 
mg/kg/min
(EFNS)
Table 3 continued.
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is considered useless; some patients need to be 
treated for weeks or months before recovering. 
Furthermore, studies defining a standard guideline 
on discontinuing the continuous infusion and 
starting the intermittent maintenance treatment 
with an AED have yet to be conducted.
Alternative Therapy for Refractory Status 
Epilepticus
The onset of RSE is mediated in part by 
γ-aminobutyric acid (GABAA) receptor 
internalisation in a condition of sustained 
neuroexcitation with consequent loss of response 
to GABA-ergic drugs.26 There is also evidence 
of increased α-amino-3-hydroxy-5-methyl-4-
isoxazolepropionic acid and N-methyl-D-aspartate 
(NMDA) receptor expression on the synaptic 
membrane, which determines increased sensitivity 
to excitatory neurotransmitters. Thus, research 
is aiming to develop drugs acting as excitatory 
antagonists/inhibitory agonists that may block 
GABAA receptor internalisation or increased 
excitatory receptor expression. Ketamine, by way 
of its NMDA channel blocking action, has been 
used on occasion with less than stellar results and 
with significant side-effects such as psychosis and 
severe neuron damage.27 
Recently, in a systematic review of inhaled 
anaesthetics used to treat RSE, Zeiler et al.28 
individuated isoflurane as an agent that can be 
used with fair efficacy (Oxford level 4, Grade D) 
after the failure of other therapies. Hypothermia is 
now routinely used in several centres around the 
world for patients with RSE despite an extremely 
small evidence base, as well as magnesium 
sulphate infusion.29 IV pyridoxine is an effective 
treatment in both rare patients with an inborn error 
of metabolism of pyridoxine and SE patients with 
no clear deficit in pyridoxine metabolism.29 Finally, 
immunotherapy with steroids, IV immunoglobulins, 
plasma exchange, or immunosuppressive drugs 
could constitute an interesting treatment choice 
in cases of SE associated with immunological 
disorders, as mentioned above.29
REFERENCES
1. Epilepsy Foundation of America. 
Treatment of convulsive status 
epilepticus: Recommendations of the 
Epilepsy Foundation of America’s 
Working Group on Status Epilepticus. 
JAMA. 1993;270(7):854-9.
2. Brophy GM et al. Guidelines for the 
evaluation and management of status 
epilepticus. Neurocrit Care. 2012;17(1): 
3-23.
3. Millikan D et al. Emergency treatment of 
status epilepticus: current thinking. Emerg 
Med Clin North Am. 2009;27(1):101-13.
4. Kovács R et al. Mechanism underlying 
blood-brain barrier dysfunction in brain 
pathology and epileptogenesis: role of 
astroglia. Epilepsia. 2012;53 Suppl 6:53-9.
5. Yu N et al. Modulation of Immunity and 
the Inflammatory Response: A New Target 
for Treating Drug-resistant Epilepsy. Curr 
Neuropharmacol. 2013;11(1):114-27.
6. Niquet J et al, “Programmed Necrosis 
After Status Epilepticus,” Noebels JL et al. 
(eds.), Jasper’s Basic Mechanisms of the 
Epilepsies (4th edition) 2012, New York 
City, NY: Oxford University Press.
7. Sutter R, Kaplan PW. 
Electroencephalographic criteria for 
nonconvulsive status epilepticus: synopsis 
and comprehensive survey. Epilepsia. 
2012;53 Suppl 3:1-51. 
8. Bauer G, Trinka E. Nonconvulsive 
status epilepticus and coma. Epilepsia. 
2010;51(2):177-90.
9. Maganti R et al. Nonconvulsive 
status epilepticus. Epilepsy Behav. 
2008;12(4):572-86.
10. Vignatelli L et al. Incidence and short-
term prognosis of status epilepticus 
in adults in Bologna, Italy. Epilepsia. 
2003;44(7):964-8.
11. Knake S et al. Incidence of status 
epilepticus in adults in Germany: a 
prospective, population-based study. 
Epilepsia. 2001;42(6):714-8.
12. Lindgren C et al. Frequency of non-
convulsive seizures and non-convulsive 
status epilepticus in subarachnoid 
hemorrhage patients in need of controlled 
ventilation and sedation. Neurocrit Care. 
2012;17(3):367-73.
13. Mecarelli O et al. EEG patterns and 
epileptic seizures in acute phase stroke. 
Cerebrovasc Dis. 2011;31(2):191-8.
14. Belcastro V et al. Non-convulsive 
status epilepticus after ischemic stroke: 
a hospital-based stroke cohort study. J 
Neurol. 2014;261(11):2136-42.
15. Holtkamp M, Meierkord H. 
Nonconvulsive status epilepticus: a 
diagnostic and therapeutic challenge 
in the intensive care setting. Ther Adv 
Neurol Disord. 2011;4(3):169-81.
16. Treiman DM et al. A progressive 
sequence of electroencephalographic 
changes during generalized convulsive 
status epilepticus. Epilepsy Res. 
1990;5(1):49-60.
17. Claassen J et al. Recommendations on 
the use of EEG monitoring in critically ill 
patients: consensus statement from the 
neurointensive care section of the ESICM. 
Intensive Care Med. 2013;39(8):1337-51.
18. Koutroumanidis M et al. “Paradoxical” 
EEG response to propofol may 
differentiate post-cardiac arrest non-
convulsive status epilepticus from diffuse 
irreversible cerebral anoxia. Epileptic 
Disord. 2014;16(4):510-7.
19. Ferlazzo E et al. Positivity to p-ANCA 
in patients with status epilepticus. BMC 
Neurol. 2014;14:148.
20. Rocco M et al. Nonconvulsive 
status epilepticus induced by acute 
Acknowledgements
To Miss Borgini for language editing.
 NEUROLOGY  •  August 2015   EMJ  EUROPEAN MEDICAL JOURNAL  NEUROLOGY  •  August 2015   EMJ  EUROPEAN MEDICAL JOURNAL 106 107
hypothyroidism in a critically ill patient. 
Intensive Care Med. 2011;37(3):553-4.
21. Vespa P et al. Increase in extracellular 
glutamate caused by reduced cerebral 
perfusion pressure and seizure 
after human traumatic brain injury: 
a microdialysis study. J Neurosurg. 
1998;89(6):971-82.
22. Cardoso A et al. Seizure-induced 
structural and functional changes 
in the rat hippocampal formation: 
comparison between brief seizures and 
status epilepticus. Behav Brain Res. 
2011;225(2):538-46. 
23. Lowenstein DH et al. The prehospital 
treatment of status epilepticus (PHTSE) 
study: design and methodology. Control 
Clin Trials. 2001;22(3):290-309. 
24. Raspall-Chaure M et al. The 
epidemiology of convulsive status 
epilepticus in children: a critical review. 
Epilepsia. 2007;48(9):1652-63.
25. Rossetti AO et al. A clinical score for 
prognosis of status epilepticus in adults. 
Neurology. 2006;66(11):1736-8.
26. Goodkin HR et al. Impact of 
receptor changes on treatment of status 
epilepticus. Epilepsia. 2007;48 Suppl 
8:14-5.
27. Mewasingh LD et al. Oral ketamine 
in paediatric non-convulsive status 
epilepticus. Seizure. 2003;12(7):483-9. 
28. Zeiler FA et al. Modern inhalational 
anesthetics for refractory status 
epilepticus. Can J Neurol Sci. 
2015;42(2):106-15.
29. Ferlisi M, Shorvon S. The outcome 
of therapies in refractory and super-
refractory convulsive status epilepticus 
and recommendations for therapy. Brain. 
2012;135(Pt 8):2314-28.
If you would like reprints of any article, contact: 01245 334450.
